🧭 Guided View
New to genetics? We explain every term as you browse, in plain English. Same pages, with the help built in.
⚡ Expert View
You already know the biology. Just the content — clean and compact, no extra explanations. This is the default view.
Bacteria-killing phage viruses souped up with DNA-destroying CRISPR appear to have helped clear up a very serious infection caused by antibiotic-resistant E. coli
The Guardian — Genetics
There is no majority support for use of gene editing on non-life-threatening conditions, writes Tom Lichy of the British Deaf Association Your editorial ( The Guardian view on…
Scientists see a positive trend toward using AI in a way that’s human, rather than as a self-driving lab. AI is simply a tool—albeit a powerful, adaptive one. The post Protecting…
In this GEN webinar, speakers from Flock Bio and Ribbon Bio will explore how bench-based, cell-free DNA production can complement expertise in custom DNA design and manufacturing. The post…
Not journalism — written in-house
Short summaries produced with AI assistance from our own database records. They are not reported by anyone else, carry no byline, and are kept separate from the news above for exactly that reason.
The CRISPR Atlas assigns every record one of four evidence levels, and understanding what each means explains why the same technology can appear in very different contexts on the same site. Laboratory research, covering five Atlas pages as of Atlas records, describes work done entirely in cells or computational models, with no human or animal testing yet. Preclinical research, spanning twelve pages, means a approach has shown results in animal models or laboratory systems rigorous enough to justify asking regulators for permission to test in people, but no human trials have begun or the programme has not advanced beyond that point. Clinical research is the largest category at fifty-nine pages and covers every stage of human trials, from early Phase I safety studies through the pivotal Phase III studies required for approval. Approved treatment, with sixteen pages, is reserved for therapies that have passed regulatory review. The distinction matters because it signals how much uncertainty remains. A preclinical finding may never translate to humans; a clinical result may still fail at a later phase. Conflating these levels risks misrepresenting experimental interventions as established ones, which is why the Atlas tracks and displays them separately.
5h agoAccording to Atlas records, the clearest divide between approved and experimental gene-editing treatments comes down to two factors: how easily cells can be removed, edited outside the body, and returned, and whether established delivery vehicles exist for reaching the relevant tissue in living patients. Casgevy, the only approved CRISPR gene-editing treatment in the Atlas, targets sickle cell disease and beta thalassemia by editing patients' own blood stem cells outside the body. Blood cells can be extracted, edited in a laboratory dish, and reinfused — a workflow that sidesteps the hard problem of delivering editing machinery into tissues inside a living person. Diseases involving internal organs present a different challenge. Conditions such as Duchenne muscular dystrophy, cystic fibrosis, Huntington's disease, and Parkinson's disease remain preclinical or at discovery stage in Atlas records, partly because reaching muscle, lung, or brain with sufficient precision and safety is unsolved. Even liver-targeted in vivo programmes, which benefit from lipid nanoparticle delivery, have encountered serious safety signals, as Atlas records for the MAGNITUDE trial illustrate. Until delivery barriers are reliably overcome, regulatory approval for those conditions remains out of reach.
5h agoAccording to Atlas records, the most significant recent developments span 2025 and 2026. The most recent entry, dated 2026, concerns lonvoguran ziclumeran (lonvo-z), a CRISPR-Cas9 therapy for hereditary angioedema. Positive Phase 3 results were reported for this in vivo gene editing approach, described in the Atlas as the first successful registrational trial of gene editing performed inside the body. A licence application is recorded as planned for the second half of 2026. That same year, the FDA reduced the default requirement from two adequate and well-controlled trials to one and issued draft guidance allowing improvement in a single participant to support approval in defined circumstances for ultra-rare diseases. From 2025, Atlas records document three notable developments. PM359, a prime editing therapy for chronic granulomatous disease, produced the first published clinical evidence that prime editing can engraft stem cells and restore immune function in patients; this carries a clinical research evidence level. Also in 2025, an infant with CPS1 deficiency received a base editor designed for his individual mutation and improved, though this remains experimental. A serious safety event also occurred: a participant in the Phase 3 MAGNITUDE trial died following severe liver injury, prompting a temporary clinical hold.
5h agoAs reflected in Atlas records, one CRISPR-based gene editing treatment has reached approval: Casgevy (exagamglogene autotemcel), which uses CRISPR-Cas9 to treat sickle cell disease and beta thalassemia. Two additional approved therapies for those same conditions — Lyfgenia and Zynteglo — use lentiviral gene addition rather than gene editing and are classified separately. At the late-stage level, four gene editing programs are in Phase III trials. Nexiguran ziclumeran targets ATTR amyloidosis, lonvoguran ziclumeran targets hereditary angioedema and reported positive Phase III results according to Atlas records, while risto-cel and BEAM-302 apply base editing to sickle cell disease and alpha-1 antitrypsin deficiency respectively. Several earlier-phase editing programs are active across cancer, familial hypercholesterolemia, chronic granulomatous disease, and diabetes. Despite this progress, the Atlas records show that conditions including Duchenne muscular dystrophy, cystic fibrosis, hemophilia, Huntington's disease, and retinitis pigmentosa remain at preclinical or discovery stages, underscoring how much of the field's ambition has yet to move into human trials.
5h agoEvery publisher the Atlas collects from, with how many of their stories it currently holds.
| Publisher | Articles held | Most recent |
|---|---|---|
| GEN — Genetic Engineering News | 11 | Aug 20, 2026 |
| Science Daily — Gene Therapy | 6 | Sep 7, 2025 |
| The Guardian — Genetics | 5 | Aug 5, 2026 |
| STAT | 4 | Aug 20, 2026 |
| Endpoints News | 3 | Aug 20, 2026 |
| Nature Genetics | 2 | Aug 20, 2026 |
| Medical Xpress — Genetics | 2 | Aug 19, 2026 |
| Science Daily | 2 | Aug 17, 2026 |
| MIT Technology Review | 2 | Aug 14, 2026 |
| New Scientist | 1 | Aug 11, 2026 |
| Science Daily — Genes | 1 | Jul 26, 2026 |
| FDA | 1 | Jul 1, 2026 |
Headlines, publisher names and links only. Articles remain the property of the publishers named. Dates are the publication dates reported by each feed, in UTC. Images, where shown, are served from the publisher and belong to them.